Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Assets (2018 - 2025)

Historic Current Assets for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $2.0 billion.

  • Revolution Medicines' Current Assets rose 2522.58% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 2522.58%. This contributed to the annual value of $2.3 billion for FY2024, which is 2385.76% up from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Current Assets is $2.0 billion, which was up 2522.58% from $2.2 billion recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Current Assets ranged from a high of $2.3 billion in Q4 2024 and a low of $483.0 million during Q2 2022
  • Moreover, its 5-year median value for Current Assets was $922.1 million (2023), whereas its average is $1.2 billion.
  • Per our database at Business Quant, Revolution Medicines' Current Assets plummeted by 2692.32% in 2022 and then soared by 18465.98% in 2023.
  • Over the past 5 years, Revolution Medicines' Current Assets (Quarter) stood at $589.8 million in 2021, then increased by 11.94% to $660.2 million in 2022, then surged by 184.66% to $1.9 billion in 2023, then increased by 23.86% to $2.3 billion in 2024, then decreased by 15.04% to $2.0 billion in 2025.
  • Its last three reported values are $2.0 billion in Q3 2025, $2.2 billion for Q2 2025, and $2.1 billion during Q1 2025.